BLB&B Advisors LLC Has $348,000 Stake in Intuitive Surgical, Inc. (NASDAQ:ISRG)

BLB&B Advisors LLC increased its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 28.6% during the 2nd quarter, Holdings Channel.com reports. The fund owned 783 shares of the medical equipment provider’s stock after acquiring an additional 174 shares during the period. BLB&B Advisors LLC’s holdings in Intuitive Surgical were worth $348,000 at the end of the most recent reporting period.

Several other institutional investors have also made changes to their positions in the business. Vanguard Group Inc. boosted its position in shares of Intuitive Surgical by 1.6% during the 1st quarter. Vanguard Group Inc. now owns 30,868,620 shares of the medical equipment provider’s stock valued at $12,319,358,000 after acquiring an additional 493,126 shares in the last quarter. Price T Rowe Associates Inc. MD raised its stake in shares of Intuitive Surgical by 1.6% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 16,973,266 shares of the medical equipment provider’s stock worth $5,726,102,000 after acquiring an additional 272,741 shares during the last quarter. Capital World Investors raised its stake in shares of Intuitive Surgical by 1.0% in the first quarter. Capital World Investors now owns 7,284,269 shares of the medical equipment provider’s stock worth $2,907,079,000 after acquiring an additional 73,634 shares during the last quarter. Edgewood Management LLC raised its stake in shares of Intuitive Surgical by 7.9% in the fourth quarter. Edgewood Management LLC now owns 5,131,066 shares of the medical equipment provider’s stock worth $1,731,016,000 after acquiring an additional 374,667 shares during the last quarter. Finally, Fisher Asset Management LLC raised its stake in shares of Intuitive Surgical by 2.0% during the fourth quarter. Fisher Asset Management LLC now owns 4,494,373 shares of the medical equipment provider’s stock worth $1,516,222,000 after buying an additional 88,977 shares during the last quarter. 83.64% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on ISRG. Citigroup boosted their price target on shares of Intuitive Surgical from $512.00 to $560.00 and gave the stock a “buy” rating in a research note on Thursday, August 22nd. Redburn Atlantic upgraded shares of Intuitive Surgical from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $380.00 to $510.00 in a report on Friday, August 2nd. Stifel Nicolaus upped their price target on shares of Intuitive Surgical from $430.00 to $475.00 and gave the company a “buy” rating in a report on Friday, July 19th. JPMorgan Chase & Co. upped their price target on shares of Intuitive Surgical from $475.00 to $495.00 and gave the company an “overweight” rating in a report on Friday, July 19th. Finally, Robert W. Baird upped their price target on shares of Intuitive Surgical from $487.00 to $503.00 and gave the company an “outperform” rating in a report on Friday, July 19th. Six equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to data from MarketBeat, Intuitive Surgical presently has a consensus rating of “Moderate Buy” and a consensus target price of $446.45.

Intuitive Surgical Price Performance

NASDAQ ISRG traded down $0.14 on Wednesday, hitting $482.21. 959,159 shares of the stock were exchanged, compared to its average volume of 1,527,626. The business’s fifty day moving average is $451.45 and its 200 day moving average is $412.69. Intuitive Surgical, Inc. has a 52 week low of $254.85 and a 52 week high of $493.97. The company has a market capitalization of $171.04 billion, a PE ratio of 87.04, a P/E/G ratio of 4.97 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last issued its quarterly earnings data on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share for the quarter, beating the consensus estimate of $1.54 by $0.24. The company had revenue of $2.01 billion for the quarter, compared to analyst estimates of $1.97 billion. Intuitive Surgical had a net margin of 27.65% and a return on equity of 13.04%. The company’s revenue was up 14.5% on a year-over-year basis. During the same period in the prior year, the firm earned $1.18 earnings per share. Analysts predict that Intuitive Surgical, Inc. will post 5.22 EPS for the current fiscal year.

Insider Activity

In other news, Director Craig H. Barratt sold 1,400 shares of the stock in a transaction dated Wednesday, June 5th. The shares were sold at an average price of $411.00, for a total value of $575,400.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In related news, EVP Robert Desantis sold 239 shares of the company’s stock in a transaction dated Monday, June 10th. The shares were sold at an average price of $416.60, for a total value of $99,567.40. Following the transaction, the executive vice president now directly owns 5,506 shares in the company, valued at $2,293,799.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Craig H. Barratt sold 1,400 shares of the company’s stock in a transaction dated Wednesday, June 5th. The shares were sold at an average price of $411.00, for a total transaction of $575,400.00. The disclosure for this sale can be found here. Insiders have sold 55,364 shares of company stock valued at $26,191,001 over the last ninety days. 0.90% of the stock is currently owned by company insiders.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.